Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]
| dc.contributor.author | National Centre for Pharmacoeconomics | |
| dc.contributor.author | COVID-19 Evidence Review Group for Medicines | |
| dc.date.accessioned | 2022-06-17T15:43:00Z | |
| dc.date.available | 2020-08-05T10:15:53Z | |
| dc.date.available | 2022-06-17T15:43:00Z | |
| dc.date.issued | 2021-02-25 | |
| dc.identifier.uri | http://hdl.handle.net/10147/628004 | |
| dc.description | There is no clear evidence that tocilizumab monotherapy has a benefit on disease progression or survival outcomes in patients with COVID-19. Tocilizumab in combination with systemic corticosteroids and SOC may reduce mortality and also avoid progression to invasive mechanical ventilation in a subset of hospitalised patients with severe COVID-19 characterised by an inflammatory phenotype (CRP ≥75 mg/L) and hypoxaemia (oxygen saturation <92% on air or requiring oxygen therapy). It is unclear if hypoxic patients with severe COVID-19 and a CRP <75mg/L would benefit from tocilizumab in combination with systemic corticosteroids. The administration of tocilizumab in combination with systemic corticosteroids is likely to offer mortality benefit in critically ill patients within 24 hours of ICU admission. No change in frequency of known or unknown adverse events have been observed in the tocilizumab arm over standard of care. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | National Centre for Pharmacoeconomics | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | CORONAVIRUS | en_US |
| dc.subject | MEDICINES | en_US |
| dc.subject | INFLAMMATORY DISEASES | en_US |
| dc.title | Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0] | en_US |
| dc.type | Report | en_US |
| refterms.dateFOA | 2020-08-05T10:15:55Z |
